Atossa Therapeutics (ATOS) unveils new regulatory strategy for low-dose (Z)-endoxifen

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. filed a current report describing a strategic update. On September 8, 2025, the company announced a new regulatory strategy intended to accelerate development of its low-dose (Z)-endoxifen product candidate for breast cancer risk reduction. The company furnished a press release with further details as an exhibit to this report.

Insights

Biopharma strategy analyst

Atossa outlines a new regulatory path to speed low-dose (Z)-endoxifen development.

Atossa Therapeutics reports a shift in regulatory strategy for its low-dose (Z)-endoxifen program, targeting breast cancer risk reduction. The stated goal is to accelerate development, which suggests a change in how the company plans to interact with regulators and structure its development plans.

The filing does not quantify timelines, approval pathways, or clinical requirements, so the concrete impact remains unclear from this excerpt alone. The press release referenced as Exhibit 99.1 is positioned as the main source of operational details behind this strategy change.

0001488039False00014880392025-09-082025-09-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2025

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
10202 5th Avenue NE, Suite 200
Seattle, Washington				98125
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check th e appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 8.01 Other Events

On September 8, 2025, Atossa Therapeutics, Inc. (the "Company") announced a new regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description of Exhibit
99.1		Press release, dated September 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	September 8, 2025	By:	/s/ Steven C. Quay
			Steven C. Quay, M.D., Ph.D. Chairman, President and Chief Executive Officer

FAQ

What did Atossa Therapeutics (ATOS) disclose in this 8-K filing?

Atossa Therapeutics disclosed that on September 8, 2025, it announced a new regulatory strategy to accelerate development of low-dose (Z)-endoxifen for breast cancer risk reduction, and it attached the related press release as an exhibit for additional information.

What is the focus of Atossa Therapeutics' new regulatory strategy?

The new strategy focuses on accelerating development of low-dose (Z)-endoxifen, a product candidate intended for breast cancer risk reduction. The filing highlights this strategic shift but leaves the specific regulatory steps and timelines to the accompanying press release referenced as Exhibit 99.1.

When did Atossa Therapeutics announce its new regulatory strategy for (Z)-endoxifen?

Atossa Therapeutics announced its new regulatory strategy on September 8, 2025. The 8-K states that this strategy aims to speed development of low-dose (Z)-endoxifen for breast cancer risk reduction and notes that further details appear in the press release filed as Exhibit 99.1.

What exhibit did Atossa Therapeutics include with this 8-K filing?

Atossa Therapeutics included Exhibit 99.1, a press release dated September 8, 2025, describing its new regulatory strategy for low-dose (Z)-endoxifen, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL version of the document.

Does Atossa’s 8-K mention financial results or transactions related to (Z)-endoxifen?

The 8-K excerpt does not mention financial results or specific transactions. It focuses on a strategic regulatory update for low-dose (Z)-endoxifen aimed at breast cancer risk reduction and points readers to a press release exhibit for more detailed narrative information.